NICE faces judicial review

Almost two years after first mooting the withdrawal of the country’s three main treatments for Alzheimer’s disease, the National Institute for Health and Clinical Excellence (NICE) this month confirmed in that use of donepezil, galantamine and rivastigmine for early stage dementia is to end.Published in a new guidance paper designed to offer support to those…